Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
11/2005
11/30/2005CN1229331C Inhibitor of monoamine uptake
11/30/2005CN1229138C Method for accelerating rate of mucociliary clearance
11/30/2005CN1229129C Adhibition ointment for relieving cough
11/30/2005CN1229114C Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
11/29/2005US6969770 reacting an alpha-keto carboxy acid ester or derivative with a pyrrolidinone to form an intermediate, subjecting the intermediate to asymmetric hydrogenation using a chiral catalyst to form the end product
11/29/2005US6969729 An indole or benz(g)indole-2,3-dione-3-oxime compounds; therapeutic treatment of respiratory disorders, urogenital disorders, cardiovascular disorders, brain and psychological disorders, gastrointestinal disorders
11/29/2005US6969724 Compounds
11/29/2005US6969723 preferably antagonists used in the therapeutic and/or preventive treatment of disfunctions of the heart, kidney, respiratory system, central nervous system
11/29/2005US6969719 Such as 3-((3-bromo-4-hydroxyphenyl)methyl)-5-ethyl-7,8-dihydro-2-(tetrahydro-2H -pyran-4-yl)amino)-3H-imidazo(2,1-b) purin-4(5H)-one for treating sexual disorders
11/29/2005US6969717 Azaindole kinase inhibitors
11/29/2005US6969713 Piperidine and piperazine acetamide derivatives
11/29/2005CA2367013C Metered dose inhaler for fluticasone propionate
11/29/2005CA2288445C 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
11/24/2005WO2005110450A1 Medicinal composition and therapeutic method
11/24/2005WO2005110359A1 Inhalation powder formulations containing enantiomerically pure beta-agonists
11/24/2005US20050261502 2-Amino-4-(1,3-benzodioxol-5-yl)-6-benzyloxy-3,5-pyridinedicarbonitrile, acting as adenosine-receptor-selective ligands, for the prophylaxis and/or treatment of cardiovascular disorders
11/24/2005US20050261368 N-(tert-butyl)-2-methoxy-2-(4-hydroxy-3-(hydroxymethyl)phen-1-yl)-ethanamine; reduced steps for synthesis while maximizing synthetic yield without sacrificing compound purity; adding D-dibenzoyltartaric acid to mixture of racemic salbutamol in methanol; crystallizing, recrystalling in second solvent
11/24/2005US20050261338 Beta2-adrenergic receptor agonists
11/24/2005US20050261333 Inhibitors of the kinase Itk; 2-aryl-substituted derivatives of 6-substituted-3H-imidazo[4,5-b]pyridines; to treat allergic, autoimmune, inflammatory, proliferative and hyperproliferative diseases and immune-mediated diseases; 6,7-dichloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine
11/24/2005US20050261331 Substituted pyrrolopyridines
11/24/2005US20050261317 Inhibitors of human phosphatidylinositol 3-kinase delta
11/24/2005US20050261313 For angiogenesis mediated diseases; cancer; acylation, cyclization and Heck-type reduction
11/24/2005US20050261305 Cyclic protein tyrosine kinase inhibitors
11/24/2005US20050261293 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/24/2005US20050261291 1-Cyclopropylmethyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine or a salt or hydrate; exhibit excellent cell adhesion inhibitory action or cell infiltration inhibitory action; for treating inflammatory diseases and autoimmune diseases such as inflammatory bowel diseases and rheumatoid arthritis
11/24/2005US20050261284 Diazinopyrimidines
11/24/2005US20050261281 Pharmaceutical compounds
11/24/2005US20050261269 New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them
11/24/2005US20050261248 New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives
11/24/2005US20050261163 Pharmaceutical products, preparation and uses thereof
11/24/2005US20050260767 Treatment with cytokines
11/24/2005US20050260601 Recombinant mutants of rhabdovirus and methods of use thereof
11/24/2005US20050260216 Polypeptide containing a mutation characteristic of an analogous non-human protein; is capable of raising antibodies in human, antibodies bind to both the human protein and the polypeptide
11/24/2005US20050260192 Leukocyte function associated antigens comprising integrin I-domain for use in identifying modulators for prevention and treatment of inflammatory disorders; immunosuppressive agents
11/24/2005US20050260174 Systems and methods for treating patients with processed lipoaspirate cells
11/24/2005CA2566877A1 Medicinal composition and therapeutic method
11/24/2005CA2565915A1 Inhalation powder formulations containing enantiomerically pure beta-agonists
11/24/2005CA2565548A1 Substituted cycloalkyl derivatives for use in the treatment of respiratory diseases
11/24/2005CA2565243A1 Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
11/24/2005CA2565026A1 Novel sustained-action bronchodilating agents for use in the treatment of respiratory diseases
11/24/2005CA2564379A1 Aerosol formulation for inhalation of beta agonists
11/24/2005CA2560103A1 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
11/24/2005CA2507712A1 Pharmaceutical compounds
11/24/2005CA2507710A1 Tricyclic pyrazole derivatives and their use as cb1 or cb2 modulators
11/23/2005EP1598340A1 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598339A1 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598338A1 1-(4-piperidinyl)-1,3-dihydro-2h-indole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598335A1 Prostaglandin derivatives
11/23/2005EP1598077A1 Use of the neurotoxic component of botulinum toxins for the treatment of a spastic muscle
11/23/2005EP1597587A2 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
11/23/2005EP1596926A2 Hypoxia induced mitogenic factor
11/23/2005EP1596856A2 Drugs containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds
11/23/2005EP1596854A2 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
11/23/2005EP1596851A1 The use of sodium 2-mercaptoethanesulfonate as antiviral agent
11/23/2005EP1596656A2 Pyrazoles and methods of making and using the same
11/23/2005EP1503754B1 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
11/23/2005EP1200831B1 Modulating binding site on potassium channels used for screening
11/23/2005EP1066261B1 Pyridine derivative and pharmaceutical containing the same
11/23/2005EP0770129B1 Zinc finger protein derivatives and methods therefor
11/23/2005CN1701061A New compounds for the inhibition of rotamases and use thereof
11/23/2005CN1700934A Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
11/23/2005CN1700922A 3, 10, and 12a substituted tetracycline compounds
11/23/2005CN1699347A Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation
11/23/2005CN1699342A New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
11/23/2005CN1228048C Medicine composition containing alpha-pinene and 1,8-eucalyptol fever-tree oil and use thereof
11/23/2005CN1228044C Water-soluble medicine particle-type slow-release composition, preparation and its preparing method
11/22/2005US6967220 antibiotics; treating respiratory system disorders; n-hydroxy benzyl formamide derivatives
11/22/2005US6967017 preservative-free mixture of water and propylene glycol; pH of 3.5 to 5.0 achieved by the addition of a concentrated strong acid; can be nebulised with currently available nebulisers
11/17/2005WO2005108400A1 Pyridoquinazoline derivatives having heterobicyclic substituents
11/17/2005WO2005108399A1 Imidazopyridine compound
11/17/2005WO2005107804A1 Therapeutic agent for respiratory ailment
11/17/2005WO2005107736A1 Cla-enriched milkfat and uses thereof
11/17/2005WO2003042399A8 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
11/17/2005US20050256315 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
11/17/2005US20050256299 Vaccines
11/17/2005US20050256211 Patient oxygenation using stabilized fluorocarbon emulsions
11/17/2005US20050256201 Phenethanolamine derivatives
11/17/2005US20050256171 Pyrrolidine derivatives as tryptase inhibitors
11/17/2005US20050256167 Preparation and use of imidazole derivatives for treatment of obesity
11/17/2005US20050256160 Beta-alanine derivatives and the use thereof
11/17/2005US20050256122 Substituted pyridazinones
11/17/2005US20050255549 IRAK-4: compositions and methods of use
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
11/17/2005US20050255151 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
11/17/2005US20050255103 Remedy for lung cancer
11/17/2005US20050255102 binds to alpha v beta 6 and not other alpha v integrins or non-specific integrins; inhibits the binding of alpha v beta 6 to latency associated peptide with an IC50 value lower than that of 10D5 and binds alpha v beta 6 in manner that does not distinguish between the use of Ca2+/Mg2+ and Mn2+ for cation
11/17/2005US20050255049 Formoterol and mometasone aerosol formulations
11/17/2005CA2566393A1 Cla-enriched milkfat and uses thereof
11/17/2005CA2566339A1 The treatment of respiratory disease
11/17/2005CA2566184A1 Imidazopyridine compound
11/17/2005CA2565170A1 The treatment of childhood asthma
11/16/2005EP1595867A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
11/16/2005EP1594547A2 Chitosan-microparticles for ifn gene delivery
11/16/2005EP1594541A2 Method and compositions for the treatment of meconium aspiration syndrome
11/16/2005EP1594537A1 Vaccination or immunization using a prime-boost regimen against brsv, bhv-1, bvdv, bpi-3
11/16/2005EP1594528A1 New pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins
11/16/2005EP1594525A1 Regulation of allergen induced gene
11/16/2005EP1594517A2 Methods and compositions for the treatment of gastrointestinal disorders
11/16/2005EP1594506A1 Benzo (1,2,5) thiadiazole als crf-antagonisten
1 ... 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 ... 878